Analyst Price Targets — NVO
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| September 11, 2026 6:20 am | Thibault Boutherin | Morgan Stanley | $40.00 | $44.01 | StreetInsider | Morgan Stanley Downgrades Novo Nordisk (NVO) to Underweight |
| August 12, 2026 7:06 am | Kerry Holford | Berenberg Bank | $47.00 | $47.17 | StreetInsider | Berenberg Downgrades Novo Nordisk (NVO) to Hold |
| August 6, 2026 11:24 am | Evan Seigerman | BMO Capital | $47.00 | $44.51 | TheFly | Novo Nordisk price target raised to $47 from $45 at BMO Capital |
| February 5, 2026 12:38 pm | — | BMO Capital | $45.00 | $47.19 | TheFly | Novo Nordisk price target lowered to $45 from $57 at BMO Capital |
| January 26, 2026 2:36 pm | Evan Seigerman | BMO Capital | $57.00 | $63.80 | StreetInsider | Novo Nordisk (NVO) PT Raised to $57 at BMO Capital |
| December 10, 2025 11:16 am | — | HSBC | $54.00 | $46.36 | TheFly | Novo Nordisk price target raised to $54 from $47 at HSBC |
| December 3, 2025 11:31 am | Thibault Boutherin | Morgan Stanley | $42.00 | $47.43 | TheFly | Novo Nordisk price target lowered to $42 from $43 at Morgan Stanley |
| November 25, 2025 9:26 am | Evan Seigerman | BMO Capital | $46.00 | $44.97 | StreetInsider | Novo Nordisk (NVO) PT Lowered to $46 at BMO Capital |
| October 14, 2025 11:29 am | Evan Seigerman | BMO Capital | $55.00 | $57.50 | TheFly | Novo Nordisk price target raised to $55 from $50 at BMO Capital |
| October 1, 2025 8:03 pm | — | HSBC | $70.00 | $59.17 | TheFly | Novo Nordisk upgraded to Buy from Hold at HSBC |
Latest News for NVO
The Danish drug giant behind Ozempic is competing with Eli Lilly in the market for weight-loss drugs.
The drugmaker said its new name aims to make it more recognizable to compete in the market for obesity medications.
Novo Nordisk said it is rebranding its name to "Novo" and updating its corporate culture, as the company works to win back market share in the obesity drug space. The Danish drugmaker called the changes the beginning of a new chapter, as it faces stiff competition from Eli Lilly and investor pressure to deliver new blockbuster products.
Novo Nordisk launched its Wegovy pill in early 2026, with Eli Lilly quickly following with a pill called Foundayo. Novo Nordisk's pill has been very well received, while Eli Lilly's pill has been slower to gain traction.
A recent clinical trial win could help Novo Nordisk expand its GLP-1 addressable market. The company is looking to bounce back after multiple setbacks.
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for NVO.
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.